Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: A thai multicenter study

• Main Authors: Khovidhunkit,W., Silaruks,S., Chaithiraphan,V., Ongphiphadhanakul,B., Sritara,P., Nimitphong,H., Benjanuwattra,T., Ambegaonkar,B.M.
• Format: Article
• Published: SAGE Publications Inc. 2015
• Subjects: Cardiology and Cardiovascular Medicine
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84866403248&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38223
• Institution: Chiang Mai University

Previous studies focused on attaining low-density lipoprotein cholesterol (LDL-C) goals after lipid-modifying therapy (LMT), but data on achieving normal levels of triglyceride and high-density lipoprotein cholesterol (HDL-C) are limited. We reviewed medical records of patients initiated on LMT. High risk was defined as patients with coronary heart disease, diabetes, or 10-year Framingham risk >20%. Among 806 patients enrolled, 429 were at high risk. Prior to initiation of LMT, 66%, 35%, and 44% overall and 69%, 35%, and 45% in the high-risk group had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. After 12 months of LMT, 21%, 32%, and 39% overall and 26%, 25%, and 43% in the high-risk group still had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. Approximately 1 of 5 patients continued to experience elevated LDL-C coupled with elevated triglyceride and/or low HDL-C. In conclusion, a substantial proportion of patients initiated on LMT continued to have lipid abnormalities. © 2012 The Author(s).